RecruitingPhase IIEN originalLung cancer

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

This phase II trial finds out the effect of local consolidative therapy and durvalumab in treating patients with stage III non-small cell lung cancer that has 3 or fewer lesions of progression (oligoprogressive) and greater than 3 lesions of progression (polyprogressive) after chemoradiation and anti-PD-l1 therapy. Local consolidative therapy, such as surgery and/or radiation, after initial treatment may kill any remaining tumor cells. Immunotherapy with durvalumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving local consolidative therapy and durvalumab may help to control the disease.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Rak płuca III stopnia (bez mutacji EGFR, ALK, ROS1, RET lub MET w gruczolakoraku, gdzie dostępne są inne leczenia)
  • Wcześniejsze leczenie chemioradioterapią i durvalumabem
  • Choroba postępująca lub pozostała po leczeniu początkowym
  • Maksymalnie 3 ogniska progresji (grupa A) lub więcej niż 3 ogniska (grupa B)
  • Możliwość otrzymania napromieniowania na co najmniej jedno ognisko
  • Badania obrazowe (tomografia, PET-CT, MRI mózgu) wykonane w ciągu 28 dni przed włączeniem
  • Wiek co najmniej 18 lat
  • Zdolność do podpisania świadomej zgody

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
August 10, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (1)

M D Anderson Cancer Center

Houston, United States

Trial contact

Joe Y Chang, MD,MS,PHD

PRINCIPAL_INVESTIGATOR

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/11/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.